Arylalkyl-thiadiazinones

ABSTRACT

Arylalkyl-thiadiazinone derivatives of the formula I    &lt;IMAGE&gt;  I  and physiologically unobjectionable salts thereof in which R1, R2, R3, R4, R5 and Q have the meanings given in claim 1, exhibit phosphodiesterase IV inhibition and can be used for the therapy of asthmatic disorders.

SUMMARY OF THE INVENTION

The invention relates to arylalkyl-thiadiazinone derivatives of theformula I ##STR2## in which R¹ and R² each independently of one anotherare H or A,

R³ and R⁴ each independently of one another are --OH, --OR¹⁰, --S--R¹⁰,--SO--R¹⁰, --SO₂ --R¹⁰, Hal, --NO₂, --NH₂, --NHR¹⁰ or --NR¹⁰ R¹¹, ortogether are methylenedioxy,

R⁵ is a phenyl radical which is unsubstituted or is mono- ordisubstituted by R⁶ and/or R⁷,

Q is absent (i.e., a single bond) or is alkylene having 1-6 carbonatoms,

R⁶ and R⁷ each independently of one another are --NH₂, --NR⁸ R⁹,--NHR¹⁰, --NR¹⁰ R¹¹, --NO₂, Hal, --CN, --OA, --COOH or --COOA,

R⁸ and R⁹ each independently of one another are H, acyl (e.g., alkanoyl)having 1-8 carbon atoms and which can be substituted by 1-5 fluorineand/or chlorine atoms, --COOA, --S--A, --SO--A, --SO₂ A, --CONH₂,--CONHA, --CONA₂, --CO--COOH, --CO--COOA, --CO--CONH₂, --CO--CONHA or--CO--CONA₂,

A is alkyl having 1-6 carbon atoms and which can be substituted by 1-5fluorine and/or chlorine atoms,

R¹⁰ and R¹ each independently of one another are A, cycloalkyl having3-7 carbon atoms, methylenecycloalkyl having 4-8 carbon atoms or alkenylhaving 2-8 carbon atoms and

Hal is F, Cl, Br or I,

and physiologically unobjectionable (e.g., pharmaceutically acceptable)salts thereof.

Thiadiazinones are known, for example, from DE 37 19 031 A1(corresponding to U.S. Pat. No. 4,916,128) and DE 41 34 893(corresponding to U.S. Pat. No. 5,276,027).

An object of the invention was to discover novel compounds havingvaluable properties, especially those compounds which can be used toprepare medicaments.

It has been found that the compounds of the formula I possess valuablepharmacological properties and in addition are of good compatibility.

In particular, they exhibit phosphodiesterase IV inhibition and can beused to treat asthmatic disorders. The antiasthmatic action can bedetermined, for example, in accordance with the method of T. Olsson,Acta allergologica 26, 438-447 (1971).

In addition, the compounds display an inhibiting action on the formationof TNF (tumor necrosis factor) and are therefore suitable for thetreatment of allergic and inflammatory diseases, autoimmune diseases andtransplant-rejection reactions. They can be employed in the treatment ofmemory disorders. The correlation of the inhibition of the tumornecrosis factor (TNF) and the treatment of diseases which are caused bythis glycoprotein is extensively described in the PCT application WO92/19594, page 3, line 33 to page 5, line 34. In WO 93/22517, compoundsare disclosed which are selective PDE IV inhibitors useful for theprophylaxis or treatment of inflammatory diseases.

The compounds can therefore be used as active medicament ingredients inhuman and veterinary medicine. They can additionally be employed asintermediates in the preparation of further active medicamentingredients.

The invention relates accordingly to the compounds of the formula I andto a process for their preparation, characterized in that a compound ofthe formula II ##STR3## in which R¹, R², R³ and R⁴ have the givenmeanings, is reacted with a compound of the formula III

    R.sup.5 --Q--X                                             III,

in which

R⁵ and Q have the meanings given and

X is Cl, Br, OH or a reactive esterified OH group,

or in that, in a compound of the formula I, one radical R⁵ is convertedinto another radical R⁵ by reducing a nitro group, acylating oralkylating a primary or a secondary amino group, or hydrolysing a cyanogroup, and/or in that a compound corresponding to the formula I butcontaining one or two free OH groups instead of R³ and/or R⁴ is, ifappropriate, reacted with a compound of the formula R³ --X or R⁴ --X,respectively, in which R³, R⁴ and X have the meanings given, and/or abase of the formula I is converted into one of its salts by treatmentwith an acid.

Above and below, the radicals R¹, R², R³, R⁴, R⁵, Q and X have themeanings given in the case of formulae I, II and III, unless expresslystated otherwise.

In the formulae, alkyl is preferably unbranched, has preferably 1, 2, 3or 4 carbon atoms and is preferably methyl, and is also preferably ethylor propyl, and is additionally preferably isopropyl, butyl, isobutyl,sec-butyl or tert-butyl, but can also be n-pentyl or isopentyl.

Cycloalkyl preferably has 3-7 carbon atoms and is preferably cyclopropylor cyclobutyl, and additionally is preferably cyclopentyl or cyclohexyl,and furthermore is cycloheptyl.

Methylenecycloalkyl preferably has 4-8 carbon atoms and is preferablymethylenecyclopropyl or methylenecyclobutyl, and is also preferablymethylenecyclopentyl or methylenecyclohexyl, and additionally ismethylenecycloheptyl.

Alkenyl is preferably vinyl, propenyl, isopropenyl, butenyl, isobutenylor sec-butenyl, and is also preferably pentenyl or isopentenyl.

Alkylene is preferably unbranched and is preferably methylene orethylene, and furthermore is preferably propylene or butylene.

Of the radicals R¹ and R², one is preferably hydrogen while the other ispreferably propyl or butyl, but with particular preference is ethyl ormethyl. Furthermore, R¹ and R² together are also each preferablyhydrogen.

The radicals R³ and R⁴ can be identical or different and are preferablyin position 3 or 4 of the phenyl ring. For example, and independently ofone another, they are hydroxyl, --S--CH₃, --SO--CH₃, --SO--CH₃, --SO₂CH₃, F, Cl, Br or I or together are methylenedioxy. With particularpreference, however, they are each methoxy, ethoxy, propoxy or else arefluoro-, difluoro- or trifluoromethoxy, or 1-fluoro-, 2-fluoro-,1,2-difluoro-, 2,2-difluoro-, 1,2,2-trifluoro- or 2,2,2-trifluoroethoxy.

The radical R⁵ is preferably phenyl. The phenyl radical is preferablymono- or disubstituted. Preferred substituents are cyano, nitro, amino,acetamido, trifluoroacetamido, methoxy and/or chlorine, and alsopreferred are methylsulfonamido, propionylamino, 2-methylpropionylamino,isobutyrylamino and/or pivalylamino, with further preferences beingmethoxycarbonylamino, methoxalylamino, ureido and/or carboxyl.

Q-R⁵ is preferably benzyl, 2-, 3- or 4-nitrobenzyl, 2-, 3- or4-cyanobenzyl, 2-, 3- or 4-aminobenzyl, 2-, 3- or 4-acetamidobenzyl, 2-,3- or 4-trifluoroacetamidobenzyl, 2-, 3- or 4-methoxybenzyl, 2-, 3- or4-chlorobenzyl, further preferences being 2-, 3- or4-methylsulfonamidobenzyl, 2-, 3- or 4-propionylaminobenzyl, 2-, 3- or4-(2-methylpropionylamino)benzyl, 2-, 3- or 4-isobutyrylaminobenzyl, 2-,3- or 4-pivalylaminobenzyl, 2-, methoxycarbonylaminobenzyl, 2-, 3- or4-ureidobenzyl, 2-, 3- or 4-carboxybenzyl, 2-, 3- or4-methoxalylaminobenzyl, and also 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-dinitrobenzyl, 2,3-, 2,4-, 2,5-, 2,6-,3,4- or 3,5-diaminobenzyl,2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-diacetamidobenzyl, 2,3-, 2,4-, 2,5-,2,6-, 3,4- or 3,5-bis(trifluoroacetamido)benzyl, 2,3-, 2,4-, 2,5-, 2,6-,3,4- or 3,5-dimethoxybenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-dichlorobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-dimethylsulfonamidobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-dipropionylaminobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-bis(2-methylpropionylamino)benzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-diisobutyrylaminobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-dipivalylaminobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-dimethoxycarbonylaminobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-dimethoxalylaminobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-diureidobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dicarboxybenzyl.

The invention relates in particular to those compounds of the formula Iin which at least one of the radicals mentioned has one of the preferredmeanings indicated above. Some preferred groups of compounds can beexpressed by the following subformulae Ia to Ie, which correspond to theformula I and in which those radicals which are not mentioned explicitlyhave the meaning given in the case of the formula I, but in which

    ______________________________________                                        in Ia   R.sup.1   is H,                                                               R.sup.2   is H or A,                                                          R.sup.3   is OA;                                                      in Ib   R.sup.1   is H,                                                               R.sup.2   is methyl or ethyl,                                                 R.sup.3 and R.sup.4                                                                     are each OA;                                                in Ic   R.sup.1   is H                                                                R.sup.2   is methyl or ethyl,                                                 R.sup.3   is OA,                                                              R.sup.4   is mono-, di- or trifluorosubstituted                                         alkyl having 1 to 6 carbon atoms;                           in Id   R.sup.1   is H,                                                               R.sup.2   is methyl or ethyl,                                                 R.sup.3 and R.sup.4                                                                     are OR.sup.10                                                       R.sup.5   is a mono- or disubstituted phenyl radical;                 and                                                                           in Ie   R.sup.1 and R.sup.2                                                                     are H,                                                              R.sup.3 and R.sup.4                                                                     are OA, and                                                         R.sup.5   is a mono- or disubstituted phenyl radical.                 ______________________________________                                    

The compounds of the formula I are otherwise prepared by methods whichare known per se and are described in the literature (for example in thestandard works such as Houben-Weyl, Methoden der Organischen Chemie,Methods of Organic Chemistry!, Georg-Thieme-Verlag, Stuttgart), andunder reaction conditions which are known and suitable for the reactionsmentioned. In this context, use can also be made of variants which areknown per se and are not mentioned in any more detail here.

In the compounds of the formula II, R¹, R², R³ and R⁴ have the meaningsgiven, especially the preferred meanings given.

In the compounds of the formula III, Q is preferably methylene orethylene, and is also preferably propylene or butylene.

In the compounds of the formula III, R⁵ has the meanings given,especially the preferred meanings given, while X is Cl, Br, OH or areactive esterified OH group.

If X is a reactive esterified OH group, it is preferablyalkylsulfonyloxy having 1-6 carbon atoms, for examplemethanesulfonyloxy, or arylsulfonyloxy having 6-10 carbon atoms, forexample benzene-, p-toluene- or 1- or 2-naphthalenesulfonyloxy.

If desired, the starting materials can also be formed in situ in such away that they are not isolated from the reaction mixture but are reactedfurther straight away to give the compounds of the formula I.Alternatively it is possible to carry out the reaction in stages.

Some of the starting materials of the formulae II and III are known.Those which are not known can be prepared by methods which are known perse.

Thiadiazinones of the formula II and their preparation, for example, aredescribed in German Patent Application P 41 34 893.

The compounds of the formula III are otherwise prepared by methods whichare known per se and are described in the literature (for example in thestandard works such as Houben-Weyl, Methoden der Organischen Chemie,Methods of Organic Chemistry!, Georg-Thieme-Verlag, Stuttgart), andunder reaction conditions which are known and suitable for the reactionsmentioned. In this context, use can also be made of variants which areknown per se and are not mentioned in any more detail here.

In detail, the reaction of the thiadiazinones of the formula II with thecompounds of the formula III takes place in the presence or absence ofan inert solvent at temperatures of between about -20° and about +150°,preferably between 20° and 100°. Examples of suitable solvents arehydrocarbons such as benzene, toluene, xylenes or mesitylene;halogenated hydrocarbons such as dichloromethane, trichloroethylene orchlorobenzene; alcohols such as methanol, ethanol or isopropanol;glycols and glycol ethers such as ethylene glycol, diethylene glycol and2-methoxyethanol; nitriles such as acetonitrile; ethers such astetrahydrofuran (THF) or dioxane; amides such as dimethylformamide (DMF)and sulfoxides such as dimethyl sulfoxide. Mixtures of these solventsare also suitable.

Furthermore, in a compound of the formula I one radical R⁵ can beconverted into another radical R⁵ by reducing a nitro group, acylatingor alkylating a primary or a secondary amino group, or hydrolysing acyano group.

It is also possible to react a compound which corresponds to the formulaI but contains one or two free OH groups instead of R³ and/or R⁴ with acompound of the formula R³ --X or R⁴ --X, respectively, in which R³, R₄the meanings given. The OH groups are etherified by methods which areknown per se and are described in standard works of the chemicalliterature (for example in Houben-Weyl, Methoden der Organischen Chemie,Methods of Organic Chemistry!, Georg-Thieme Verlag, Stuttgart or inOrganic Reactions, John Wiley & Sons Inc., New York), under reactionconditions which are known and suitable for the reactions mentioned. Inthis context, use can also be made of variants which are known per seand which are not mentioned here in any more detail.

A base of the formula I which is obtained can be converted with an acidinto the corresponding acid addition salt. Acids suitable for thisreaction are those which give physiologically unobjectionable salts. Forinstance, it is possible to use inorganic acids, for example sulfuricacid, hydrohalic acids such as hydrochloric acid or hydrobromic acid,phosphoric acids such as orthophosphoric acid, nitric acid, sulfamicacid, and also organic acids, specifically aliphatic, alicyclic,araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic,sulfonic or sulfuric acids, such as formic acid, acetic acid, propionicacid, pivalic acid, diethylacetic acid, malonic acid, succinic acid,pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid,malic acid, benzoic acid, salicylic acid, 2-phenylpropionic acid, citricacid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid,methane- or ethanesulfonic acid, ethanedisulfonic acid,2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonicacid, naphthalenemono- and -disulfonic acids, and laurylsulfuric acid.

The free bases of the formula I can if desired se liberated from theirsalts by treatment with strong bases, such as sodium hydroxide orpotassium hydroxide, sodium carbonate or potassium carbonate.

Compounds of the formula I may contain one or more centers of asymmetry.In this case they are usually in racemic form. All racemates which areobtained can be separated into their enantiomers mechanically orchemically by methods which are known per se. Preferably, diastereomersare formed from the racemic mixture by reaction with an optically activeseparating agent.

It is of course also possible to obtain optically active compounds ofthe formula I by the methods described above using starting materialswhich are already optically active.

This formula I embraces all stereoisomers and mixtures thereof, forexample the racemates.

The invention additionally relates to the use of the compounds of theformula I and their physiologically unobjectionable salts for theproduction of pharmaceutical preparations, especially by a non-chemicalmethod. In this context they can be brought, together with at least onesolid, liquid and/or semiliquid excipient or auxiliary and, if desired,in combination with one or more further active ingredients, into asuitable dosage form.

The invention additionally relates to compositions, especiallypharmaceutical preparations, comprising at least one compound of theformula I and/or one of its physiologically unobjectionable salts.

These preparations can be used as medicaments in human or veterinarymedicine. Suitable excipients are organic or inorganic substances whichare suitable for enteral (e.g., oral), parenteral or topical applicationand which do not react with the novel compounds, examples being water,vegetable oils, benzyl alcohols, polyethylene glycols, glyceroltriacetate, gelatin, carbohydrates such as lactose or starch, magnesiumstearate, talc and petroleum jelly. For oral administration use is madein particular of plain tablets, coated tablets, capsules, syrups, juicesor drops, for rectal administration of suppositories, for parenteraladministration of solutions, preferably oily or aqueous solutions, andalso suspensions, emulsions or implants, and for topical application ofointments, creams or powders. The novel compounds can also belyophilized and the resulting lyophilizates used, for example, toproduce preparations for injection. The preparations indicated can besterilized and/or can contain auxiliaries such as glidants,preservatives, stabilizers and/or wetting agents, emulsifiers, salts forinfluencing the osmotic pressure, buffer substances, colorants,flavorings and or aroma substances. If desired they can also compriseone or more other active ingredients, for example one or more vitamins.

The compounds of the formula I can be used to combat diseases,especially asthmatic disorders, and in the therapeutic treatment of thehuman or animal body.

In this context the substances according to the invention are generallyadministered in analogy to known antiasthmatics, such as Atrovent®,preferably in doses of between about 1 and 100 mg, in particular between2 and 20 mg, per dosage unit. The daily dose is preferably between about0.02 and 2 mg/kg of body weight. The specific dose for each particularpatient depends, however, on a wide variety of factors, for example onthe effectiveness of the specific compound employed, on the age, bodyweight, general condition of health, sex, on the diet, on the time androute of administration, on the speed of excretion, on the combinationof medicaments and on the severity of the particular disease to whichthe therapy is applied. Adjustment of the dosage for these factors isroutine and conventional in the art. Oral administration is preferred.

Without further elaboration, it is believed that one skilled in the artcan, using the preceding description, utilize the present invention toits fullest extent. The following preferred specific embodiments are,therefore, to be construed as merely illustrative, and not limitative ofthe remainder of the disclosure in any way whatsoever.

In the foregoing and in the following examples, all temperatures are setforth uncorrected in degrees Celsius and unless otherwise indicated, allparts and percentages are by weight.

The entire disclosure of all applications, patents and publications,cited above and below, and of corresponding German application P 195 02699.3, filed Jan. 28, 1995, are hereby incorporated by reference.

In the examples, "worked up in the conventional manner" means:

water or dilute aqueous sodium hydroxide solution is added if necessary,extraction is carried out with an organic solvent such as ethyl acetate,chloroform or dichloromethane, the phases are separated, the organicphase is dried over sodium sulfate, filtered and concentrated byevaporation and the residue is purified by chromatography and/orcrystallization.

EXAMPLES Example 1

A solution of 2.8 g of5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one ("A")obtainable by reacting 1-(3,4-dimethoxyphenyl)-2-bromobutan-1-one withmethyl hydrazinethioformate! in 150 ml of acetone is boiled with 3 g of4-nitrobenzyl chloride in the presence of 4 g of potassium carbonate foreight hours. The insoluble residue is filtered off and the solution isconcentrated. The residue is worked up in the conventional manner togive3-(4-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2oil.

The following compounds are obtained analogously by reacting "A":

with 3-nitrobenzyl chloride:

3-(3-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 2-nitrobenzyl chloride:

3-(2-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 2,3-dinitrobenzyl chloride:

3-(2,3-dinitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 2,4-dinitrobenzyl chloride:

3-(2,4-dinitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 2-methoxybenzyl chloride:

3-(2-methoxybenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 4-methoxybenzyl chloride:

3-(4-methoxybenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 120°;

with 2-chlorobenzyl chloride:

3-(2-chlorobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 77°;

with 2,6-dichlorobenzyl chloride:

3-(2,6-dichlorobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 187°;

with 4-cyanobenzyl chloride:

3-(4-cyanobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 4-carboxybenzyl chloride:

3-(4-carboxybenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 106°.

Example 2

In analogy to Example 1, the reaction of5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one ("B") with4-nitrobenzyl chloride gives3-(4-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 155°.

The following compounds are obtained analogously by reacting "B":

with 3-nitrobenzyl chloride:

3-(3-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro1,3,4-thiadiazin-2-one;

with 2,4-dinitrobenzyl chloride:

3-(2,4-dinitrobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 4-methoxybenzyl chloride:

3-(4-methoxybenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 2-chlorobenzyl chloride:

3-(2-chlorobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 2,6-dichlorobenzyl chloride:

3-(2,6-dichlorobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 4-cyanobenzyl chloride:

3-(4-cyanobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one.

Example 3

In analogy to Example 1, the reaction of5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-onewith 4-nitrobenzyl chloride ("C") gives3-(4-nitrobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting "C":

with5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazine-2-one:

3-(4-nitrobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-nitrobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-nitrobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with 5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-nitrobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-nitrobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-nitrobenzyl)-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-nitrobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with5-(3-hydroxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-nitrobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with5-(4-methylsulfonylphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-nitrobenzyl)-5-(4-methylsulfonylphenyl)-6-ethyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with5-(3,4-methyleneoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazine-2-one:

3-(4-nitrobenzyl)-5-(3,4-methyleneoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

Example 4

A solution of 3.9 g of3-(4-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-onein 40 ml of tetrahydrofuran is hydrogenated in the presence of Raneynickel. The catalyst is filtered off and the solution is concentrated.Recrystallization gives3-(4-aminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 105°.

The following compounds are obtained analogously by reaction:

of3-(3-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(3-aminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 112°;

of3-(2-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(2-aminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(2,3-dinitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(2,3-diaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(2,4-dinitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(2,4-diaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

3-(4-aminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(4-methylsulfonylphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(4-methylsulfonylphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3,4-methyleneoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3,4-methyleneoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 132°;

of3-(4-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

3-(4-aminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-one;

of3-(3-nitrobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(3-aminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 176°;

of3-(4-nitrobenzyl)-5-(4-ethoxy-3-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(4-ethoxy-3-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-methoxy-4-difluoromethoxy-phenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiazin-2-one:

3-(4-aminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

of3-(4-nitrobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one.

Example 5

10 g of3-(4-cyanobenzyl)-5-(3,4-dihydroxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-oneare added with stirring to a cooled solution of 1.3 g of NaOH in 100 mlof water and the mixture is subsequently stirred for 10 hours.

The solution is carefully heated, during which a stream of air is passedthrough it. Cooled sulfuric acid and water are then added. The mixtureis worked up in the conventional manner to give3-(4-carboxybenzyl)-5-(3,4-dihydroxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 106°.

Example 6

0.8 ml of trifluoroacetyl chloride is added with stirring and icecooling to a solution of 1.4 g of3-(4-aminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one("D") in 60 ml of dichloromethane and 1 ml of triethylamine, and themixture is subsequently stirred for 3 hours. The solvent is removed andthe residue is worked up in the conventional manner. Recrystallizationfrom isopropanol/petroleum ether gives 1.9 g of3-(4-trifluoroacetamidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 124°.

The following compounds are obtained analogously by reacting "D":

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-oneas an oil, MS (EI) M⁺ 427;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous, MS (EI) M⁺ 463;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous, MS (EI) M⁺ 441;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous, MS (EI) M⁺ 455;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 141°;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 155°;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 115°;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3,4-dimethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous, MS (EI) M⁺ 457;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous, MS (EI) M⁺ 472;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 140°;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 77°;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 113°.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 155°;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonylamidobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 136°;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 160° C.;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous, MS (EI) M⁺ 481;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 146°;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidophenethyl)-5-(3,4-dimethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 112°;

with methylsulfonyl chloride:

3-(4-methylsulfonamidophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylphenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminophenethyl)-5-(3,4-di-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(3-aminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(3-trifluoroacetamidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous, MS (EI) M⁺ 481;

with acetyl chloride:

3-(3-acetamidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(3-methylsulfonamidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(3-propionylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 159°;

with cyclopentanecarboxylic acid:

3-(3-cyclopentylcarbamoylbenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(3-isobutyrylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(3-methoxycarbonylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(3-ethoxycarbonylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,amorphous;

with methoxalyl chloride:

3-(3-methoxalylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(3-ureidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(3-butyrylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(3-pentanoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(3-hexanoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(3-pentafluoropropionylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(3-pivalylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 176°;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 186°;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 186°;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 137°;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 188°;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 184°;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 95°;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-ethoxy-4-methoxy-phenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 196°;

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 103°;

with isobutyryl chloride:

3-(4-isobutyrylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 72°;

with pivalyl chloride:

3-(4-pivalylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylbenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(4-aminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(4-trifluoroacetamidophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(4-acetamidophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(4-propionylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(4-isobutyrylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(4-methoxycarbonylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(4-ethoxycarbonylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(4-pivalylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(4-methoxalylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(4-ureidophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(4-butyrylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(4-pentanoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(4-hexanoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(4-pentafluoropropionylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(4-cyclopentylcarbamoylphenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one.

The following compounds are obtained analogously by reacting3-(3-aminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one:

with trifluoroacetyl chloride:

3-(3-trifluoroacetamidobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with acetyl chloride:

3-(3-acetamidobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methylsulfonyl chloride:

3-(4-methylsulfonamidobenzyl)-5(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with propionyl chloride:

3-(3-propionylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with isobutyryl chloride:

3-(3-isobutyrylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methyl chloroformate:

3-(3-methoxycarbonylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with ethyl chloroformate:

3-(3-ethoxycarbonylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pivalyl chloride:

3-(3-pivalylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with methoxalyl chloride:

3-(3-methoxalylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with chloroformamide:

3-(3-ureidobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with butyryl chloride:

3-(3-butyrylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentanoyl chloride:

3-(3-pentanoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with hexanoyl chloride:

3-(3-hexanoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with pentafluoropropionyl chloride:

3-(3-pentafluoropropionylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;

with cyclopentanecarbonyl chloride:

3-(3-cyclopentylcarbamoylbenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one.

Example 7

1.5 ml of butyl bromide dissolved in 20 ml of dichloromethane is addedwith stirring and cooling to a solution of 1.4 g of3-(4-aminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-onein 60 ml of dichloromethane and 1 ml of triethylamine, and the mixtureis subsequently stirred for 3 hours. The solvent is removed and theresidue is worked up in the conventional manner, to give3-(4-N,N-dibutylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

Example 8

One equivalent of trifluoromethyl iodide is added to a solution of 1.4 gof 3-(4-propionylaminobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6- ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one obtainable by reacting3-(4-aminobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-onewith propionyl chloride! in THF, and the mixture is then boiled for twohours.

The solvent is subsequently removed and the residue is worked up in theconventional manner, to give3-(4-propionylamino)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

Example 9

The following compounds are obtained analogously by reaction

of3-(2-nitrobenzyl)-5-(3,4-dimethoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(2-aminobenzyl)-5-(3,4-dimethoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one("E"), m.p. 127°;

of3-(4-nitrobenzyl)-5-(3-propoxy-4-methoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-propoxy-4-methoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 125°;

of3-(4-nitrobenzyl)-5-(3-cyclopentyloxy-4-methoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one:

3-(4-aminobenzyl)-5-(3-cyclopentyloxy-4-methoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 123°.

Example 10

The following compounds are obtained in analogy to Example 6 by reacting"E":

with acetyl chloride:

3-(2-acetamidobenzyl)-5-(3,4-dimethoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 210°;

with trifluoroacetyl chloride:

3-(2-trifluoroacetamidobenzyl)-5-(3,4-dimethoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 200°.

The following compounds are obtained by reacting3-(4-aminobenzyl)-5-(3-propoxy-4-methoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one:

with acetyl chloride:

3-(4-acetamidobenzyl)-5-(3-propoxy-4-methoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one,no defined melting point, amorphous;

with propionyl chloride:

3-(4-propionylaminobenzyl)-5-(3-propoxy-4-methoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 150°;

with trifluoroacetyl chloride:

3-(4-trifluoroacetamido)-5-(3-propoxy-4-methoxy)-3,6-dihydro-1,3,4-thiadiazin-2-one,m.p. 167°.

The examples which follow relate to pharmaceutical preparations:

Example A

Injection vials

A solution of 100 g of an active ingredient of the formula I and 5 g ofdisodium-hydrogen phosphate in 3 l of double-distilled water is adjustedto a pH of 6.5 using 2 N hydrochloric acid, subjected to sterilefiltration, dispensed into injection vials and lyophilized under sterileconditions and the vials are sealed in a sterile manner. Each injectionvial contains 5 mg of active ingredient.

Example B

Suppositories

A mixture of 20 g of an active ingredient of the formula I is meltedwith 100 g of soya lecithin and 1400 g of cocoa butter and the mixtureis poured into molds and allowed to cool. Each suppository contains 20mg of active ingredient.

Example C

Solution

A solution is prepared from 1 g of an active ingredient of the formulaI, 9.38 g of NaH₂ PO₄.2 H₂ O, 28.48 g of Na₂ HPO ₄.12 H₂ O and 0.1 g ofbenzalkonium chloride in 940 ml of double-distilled water. The solutionis adjusted to a pH of 6.8, made up to 1 l and sterilized byirradiation. This solution can be used in the form of eyedrops.

Example D

Ointment

500 mg of an active ingredient of the formula I are mixed with 99.5 g ofpetroleum jelly under aseptic conditions.

Example E

Tablets

A mixture of 1 kg of active ingredient of the formula I, 4 kg oflactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesiumstearate is pressed in a customary manner to give tablets, such thateach tablet contains 10 mg of active ingredient.

Example F

Coated tablets

Tablets are pressed in analogy to Example E and are when coated in acustomary manner with a coating of sucrose, potato starch, talc, gumtragacanth and colorant.

Example G

Capsules

Hard gelatin capsules are filled in a customary manner with 2 kg ofactive compound of the formula I such that each capsule contains 20 mgof the active ingredient.

Example H

Ampoules

A solution of 1 kg of active ingredient of the formula I in 60 1 ofdouble-distilled water is subjected to sterile filtration, dispensedinto ampoules and lyophilized under sterile conditions, and the ampoulesare sealed in a sterile manner. Each ampoule contains 10 mg of activeingredient.

The preceding examples can be repeated with similar success bysubstituting the generically or specifically described reactants and/oroperating conditions of this invention for those used in the precedingexamples.

From the foregoing description, one skilled in the art can easilyascertain the essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make various changesand modifications of the invention to adapt it to various usages andconditions.

What is claimed is:
 1. An arylalkyl-thiadiazinone compound of formula I##STR4## wherein R¹ and R² are each independently H or A,R³ and R⁴ areeach independently --OH, --OR¹⁰, --S--R¹⁰, --SO--R¹⁰, --SO₂ --R¹⁰, Hal,methylenedioxy, --NO₂, --NH₂, --NHR¹⁰ or --NR¹⁰ R¹¹, R⁵ is a phenylradical which is unsubstituted or is mono- or disubstituted by R⁶ and/orR⁷, Q is absent or is C₁₋₆ -alkylene, R⁶ and R⁷ are each independently--NH₂, --NR⁸ R⁹, --NHR₁₀, --NR¹⁰ R¹¹, --NO₂, Hal, --CN, --OA, --COOH or--COOA, R⁸ and R⁹ are each independently H, C₁₋₈ -alkanoyl optionallysubstituted by 1-5 fluorine and/or chlorine atoms, --COOA, --S--A,--SO--A, --SO₂ A, --CONH₂, --CONHA, --CONA₂, --CO--COOH, --CO--COOA,--CO--CONH₂, --CO--CONHA or --CO--CONA₂, A is C₁₆ -alkyl optionallysubstituted by 1-5 fluorine and/or chlorine atoms, R¹⁰ and R¹¹ are eachindependently A, C₃₋₇ --cycloalkyl, C₄₋₈ -methylenecycloalkyl or C₂₋₈-alkenyl, and Hal is F, Cl, Br or I, or a physiologically acceptablesalt thereof.
 2. A compound according to claim 1, wherein R¹ is H, R² isH or A, and R³ is OA.
 3. A compound according to claim 1, wherein R¹ isH, R² is methyl or ethyl, and R³ and R⁴ are each OA.
 4. A compoundaccording to claim 1, wherein R¹ is H, R² is methyl or ethyl, R³ is OA,and R⁴ is mono-, di- or trifluorosubstituted alkyl having 1 to 6 carbonatoms.
 5. A compound according to claim 1, wherein R¹ is H, R² is methylor ethyl, R³ and R⁴ are OR¹⁰, and R⁵ is a mono-or disubstituted phenylradical.
 6. A compound according to claim 1, wherein R¹ and R² are H, R³and R⁴ are OA, and R⁵ is a mono- or disubstituted phenyl radical.
 7. Acompound according to claim 1, which is:(a)3-(4-Nitrobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;(b)3-(4-aminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;(c)3-(4-trifluoroacetamidobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;(d)3-(4-acetamidobenzyl)-5-(3,4-dimethoxy-phenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one;(e)3-(4-methoxybenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one;or (f)3-(2,6-dichlorobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one.8. A pharmaceutical composition comprising one or more compounds offormula I according to claim 1 or physiologically acceptable saltsthereof, and a pharmaceutically acceptable carrier.